Mesenchymal stem cells for systemic therapy: Shotgun approach or magic bullets?

BioEssays

Volumn 35, Issue 3, 2013, Pages 173-182

  Millard, Susan M ^a   Fisk, Nicholas M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Mesenchymal stem cell; Regenerative medicine; Stem cell therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; NANOPARTICLE; PRODRUG; REMESTEMCEL L;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL HOMING; CELL ISOLATION; CELL PROLIFERATION; CHIMERA; CHRONIC DISEASE; DNA MODIFICATION; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; ENGRAFTMENT; EXOSOME; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; STEM CELL EXPANSION; STEM CELL NICHE; TISSUE REPAIR; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; EXOSOMES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PARACRINE COMMUNICATION; WOUND HEALING;

EID: 84873568958     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201200087     Document Type: Article

References (116)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. 1968. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6: 230-47.
2. Friedenstein AJ, Piatetzky S II, Petrakova KV. 1966. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 16: 381-90.
3. Horwitz EM, Le Blanc K, Dominici M, Mueller I, et al. 2005. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-5.
4. Eaves C, Miller C, Conneally E, Audet J, et al. 1999. Introduction to stem cell biology in vitro. Threshold to the future. Ann N Y Acad Sci 872: 1-8.
5. Caplan AI. 1991. Mesenchymal stem cells. J Orthop Res 9: 641-50.
6. Prockop DJ. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-4.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, et al. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-7.
8. Bader A, Macchiarini P. 2010. Moving towards in situ tracheal regeneration: The bionic tissue engineered transplantation approach. J Cell Mol Med 14: 1877-89.
9. Baiguera S, Birchall MA, Macchiarini P. 2010. Tissue-engineered tracheal transplantation. Transplantation 89: 485-91.
10. Kidd S, Spaeth E, Dembinski JL, Dietrich M, et al. 2009. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27: 2614-23.
11. Reagan MR, Kaplan DL. 2011. Concise review: Mesenchymal stem cell tumor-homing: Detection methods in disease model systems. Stem Cells 29: 920-7.
12. Carney BJ, Shah K. 2011. Migration and fate of therapeutic stem cells in different brain disease models. Neuroscience 197: 37-47.
13. Gyongyosi M, Blanco J, Marian T, Tron L, et al. 2008. Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. Circ Cardiovasc Imaging 1: 94-103.
14. Hou D, Youssef EA, Brinton TJ, Zhang P, et al. 2005. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials. Circulation 112: I150-6.
15. Bantubungi K, Blum D, Cuvelier L, Wislet-Gendebien S, et al. 2008. Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci 37: 454-70.
16. Karp JM, Leng Teo GS. 2009. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 4: 206-16.
17. Pistoia V, Raffaghello L. 2011. Damage-associated molecular patterns (DAMPs) and mesenchymal stem cells: A matter of attraction and excitement. Eur J Immunol 41: 1828-31.
18. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, et al. 2006. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24: 1254-64.
19. Cheng Z, Ou L, Zhou X, Li F, et al. 2008. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16: 571-9.
20. Cheng H, Byrska-Bishop M, Zhang CT, Kastrup CJ, et al. 2012. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. Biomaterials 33: 5004-12.
21. Sarkar D, Spencer JA, Phillips JA, Zhao W, et al. 2011. Engineered cell homing. Blood 118: e184-91.
22. Guan M, Yao W, Liu R, Lam KS, et al. 2012. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 18: 456-62.
23. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, et al. 2009. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA 106: 14022-7.
24. Lee RH, Pulin AA, Seo MJ, Kota DJ, et al. 2009. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63.
25. Roddy GW, Oh JY, Lee RH, Bartosh TJ, et al. 2011. Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 29: 1572-9.
26. Togel F, Cohen A, Zhang P, Yang Y, et al. 2009. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 18: 475-85.
27. Guillot PV, Abass O, Bassett JH, Shefelbine SJ, et al. 2008. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 111: 1717-25.
28. Vanleene M, Saldanha Z, Cloyd KL, Jell G, et al. 2011. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multi-scale tissue properties. Blood 117: 1053-60.
29. Panaroni C, Gioia R, Lupi A, Besio R, et al. 2009. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 114: 459-68.
30. Horwitz EM, Gordon PL, Koo WK, Marx JC, et al. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-7.
31. Otsuru S, Gordon PL, Shimono K, Jethva R, et al. 2012. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 120: 1933-41.
32. Chen L, Tredget EE, Liu C, Wu Y. 2009. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One 4: e7119.
33. Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, et al. 2010. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122: 2419-29.
34. von Bahr L, Batsis I, Moll G, Hagg M, et al. 2012. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 30: 1575-8.
35. Gebler A, Zabel O, Seliger B. 2012. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 18: 128-34.
36. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, et al. 2009. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27: 2865-74.
37. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, et al. 2009. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-9.
38. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, et al. 2009. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 182: 5994-6002.
39. Griffin MD, Ritter T, Mahon BP. 2010. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21: 1641-55.
40. Gotherstrom C, Lundqvist A, Duprez IR, Childs R, et al. 2011. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 13: 269-78.
41. Choi H, Lee RH, Bazhanov N, Oh JY, et al. 2011. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 118: 330-8.
42. Krampera M. 2011. Mesenchymal stromal cell 'licensing': A multistep process. Leukemia 25: 1408-14.
43. Singer NG, Caplan AI. 2011. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 6: 457-78.
44. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. 2010. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
45. Kebriaei P, Robinson S. 2011. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 13: 262-8.
46. Timmers L, Lim SK, Arslan F, Armstrong JS, et al. 2007. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 1: 129-37.
47. Timmers L, Lim SK, Hoefer IE, Arslan F, et al. 2011. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 6: 206-14.
48. Ratajczak MZ, Kucia M, Jadczyk T, Greco NJ, et al. 2012. Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: Can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? Leukemia 26: 1166-73.
49. Gatti S, Bruno S, Deregibus MC, Sordi A, et al. 2011. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26: 1474-83.
50. Cantaluppi V, Gatti S, Medica D, Figliolini F, et al. 2012. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82: 412-27.
51. Islam MN, Das SR, Emin MT, Wei M, et al. 2012. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18: 759-65.
52. Deyle DR, Khan IF, Ren G, Wang PR, et al. 2012. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther 20: 204-13.
53. Huang J, Zhang Z, Guo J, Ni A, et al. 2010. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 106: 1753-62.
54. Liu XH, Bai CG, Xu ZY, Huang SD, et al. 2008. Therapeutic potential of angiogenin modified mesenchymal stem cells: Angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc Res 76: 23-30.
55. Yang F, Cho SW, Son SM, Bogatyrev SR, et al. 2010. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci USA 107: 3317-22.
56. Bao C, Guo J, Zheng M, Chen Y, et al. 2010. Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection. Biochem Cell Biol 88: 629-34.
57. Manning E, Pham S, Li S, Vazquez-Padron RI, et al. 2010. Interleukin-10 delivery via mesenchymal stem cells: A novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 21: 713-27.
58. Granero-Molto F, Myers TJ, Weis JA, Longobardi L, et al. 2011. Mesenchymal stem cells expressing insulin-like growth factor-I (MSCIGF) promote fracture healing and restore new bone formation in Irs1 knockout mice: Analyses of MSCIGF autocrine and paracrine regenerative effects. Stem Cells 29: 1537-48.
59. Pagnotto MR, Wang Z, Karpie JC, Ferretti M, et al. 2007. Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. Gene Ther 14: 804-13.
60. Zachos T, Diggs A, Weisbrode S, Bartlett J, et al. 2007. Mesenchymal stem cell-mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model. Mol Ther 15: 1543-50.
61. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, et al. 2007. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 15: 1910-6.
62. Meyerrose T, Olson S, Pontow S, Kalomoiris S, et al. 2010. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 62: 1167-74.
63. Benabdallah BF, Allard E, Yao S, Friedman G, et al. 2010. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. Cytotherapy 12: 394-9.
64. Wang H, Cao F, De A, Cao Y, et al. 2009. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 27: 1548-58.
65. Klopp AH, Gupta A, Spaeth E, Andreeff M, et al. 2011. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-9.
66. Sun XY, Nong J, Qin K, Warnock GL, et al. 2011. Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells 3: 96-103.
67. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, et al. 2009. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-7.
68. Detante O, Moisan A, Dimastromatteo J, Richard MJ, et al. 2009. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: In vivo imaging and biodistribution. Cell Transplant 18: 1369-79.
69. Lee ES, Chan J, Shuter B, Tan LG, et al. 2009. Microgel iron oxide nanoparticles for tracking human fetal mesenchymal stem cells through magnetic resonance imaging. Stem Cells 27: 1921-31.
70. Nam SY, Ricles LM, Suggs LJ, Emelianov SY. 2012. In vivo ultrasound and photoacoustic monitoring of mesenchymal stem cells labeled with gold nanotracers. PLoS One 7: e37267.
71. Elsabahy M, Wooley KL. 2012. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41: 2545-61.
72. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, et al. 2012. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 41: 2971-3010.
73. Li L, Guan Y, Liu H, Hao N, et al. 2011. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 5: 7462-70.
74. Sarkar D, Ankrum JA, Teo GS, Carman CV, et al. 2011. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials 32: 3053-61.
75. Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, et al. 2010. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev 19: 481-90.
76. Roche S, Delorme B, Oostendorp RA, Barbet R, et al. 2009. Comparative proteomic analysis of human mesenchymal and embryonic stem cells: Towards the definition of a mesenchymal stem cell proteomic signature. Proteomics 9: 223-32.
77. Wagner W, Wein F, Seckinger A, Frankhauser M, et al. 2005. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33: 1402-16.
78. Martens TP, See F, Schuster MD, Sondermeijer HP, et al. 2006. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 3: S18-22.
79. Poloni A, Rosini V, Mondini E, Maurizi G, et al. 2008. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy 10: 690-7.
80. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, et al. 2007. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: Comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 16: 931-52.
81. Bruder SP, Jaiswal N, Haynesworth SE. 1997. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 64: 278-94.
82. Kern S, Eichler H, Stoeve J, Kluter H, et al. 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24: 1294-301.
83. Lu LL, Liu YJ, Yang SG, Zhao QJ, et al. 2006. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91: 1017-26.
84. Barlow S, Brooke G, Chatterjee K, Price G, et al. 2008. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 17: 1095-107.
85. Guillot PV, Gotherstrom C, Chan J, Kurata H, et al. 2007. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 25: 646-54.
86. Baksh D, Yao R, Tuan RS. 2007. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25: 1384-92.
87. Zhang ZY, Teoh SH, Chong MS, Schantz JT, et al. 2009. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells 27: 126-37.
88. Chen YS, Pelekanos RA, Ellis RL, Horne R, et al. 2012. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Trans Med 1: 83-95.
89. Jung Y, Bauer G, Nolta JA. 2012. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products. Stem Cells 30: 42-7.
90. Lai RC, Choo A, Lim SK. 2011. Derivation and characterization of human ESC-derived mesenchymal stem cells. Methods Mol Biol 698: 141-50.
91. Hussein SMI, Elbaz J, Nagy AA. 2013. Genome damage in induced pluripotent stem cells: Assessing the mechanisms and their consequences. BioEssays 35, in press, DOI: 10.1002/bies.201200114.
92. Pera MF. 2011. Stem cells: The dark side of induced pluripotency. Nature 471: 46-7.
93. Zwaka TP. 2010. Stem cells: Troublesome memories. Nature 467: 280-1.
94. Potapova IA, Brink PR, Cohen IS, Doronin SV. 2008. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 283: 13100-7.
95. Frost J, Monk D, Moschidou D, Guillot PV, et al. 2011. The effects of culture on genomic imprinting profiles in human embryonic and fetal mesenchymal stem cells. Epigenetics 6: 52-62.
96. Ben-David U, Mayshar Y, Benvenisty N. 2011. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 9: 97-102.
97. Csaszar E, Cohen S, Zandstra PW. 2013. Blood stem cell products: Toward sustainable benchmarks for clinical translation. BioEssays 35, in press, DOI: 10.1002/bies.201200118.
98. Le Blanc K. 2003. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5: 485-9.
99. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, et al. 2004. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 190: 239-45.
100. Guillot PV, De Bari C, Dell'Accio F, Kurata H, et al. 2008. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation 76: 946-57.
101. Gotherstrom C, Ringden O, Westgren M, Tammik C, et al. 2003. Immunomodulatory effects of human fetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 32: 265-72.
102. Zhang ZY, Teoh SH, Hui JH, Fisk NM, et al. 2012. The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application. Biomaterials 33: 2656-72.
103. Roelen DL, van der Mast BJ, in't Anker PS, Kleijburg C, et al. 2009. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol 70: 16-23.
104. Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, et al. 2011. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 20: 655-67.
105. Polchert D, Sobinsky J, Douglas G, Kidd M, et al. 2008. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38: 1745-55.
106. Clifford DM, Fisher SA, Brunskill SJ, Doree C, et al. 2012. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2: CD006536.
107. Lu D, Chen B, Liang Z, Deng W, et al. 2011. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 92: 26-36.
108. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, et al. 2009. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 52: 79-86.
109. Hare JM, Traverse JH, Henry TD, Dib N, et al. 2009. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54: 2277-86.
110. Le Blanc K, Frassoni F, Ball L, Locatelli F, et al. 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371: 1579-86.
111. Allison M. 2009. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27: 966-7.
112. Wernicke CM, Grunewald TG, Juenger H, Kuci S, et al. 2011. Mesenchymal stromal cells for treatment of steroid-refractory GvHD: A review of the literature and two pediatric cases. Int Arch Med 4: 27.
113. Penn MS, Ellis S, Gandhi S, Greenbaum A, et al. 2012. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase I clinical study. Circ Res 110: 304-11.
114. Van Harmelen V, Rohrig K, Hauner H. 2004. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metabolism 53: 632-7.
115. Abumaree MH, Al Jumah MA, Kalionis B, Jawdat D, et al. 2012. Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Rev and Rep: 1-16.
116. Campagnoli C, Roberts IA, Kumar S, Bennett PR, et al. 2001. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98: 2396-402.